Mirum Pharmaceuticals (MIRM) Is Up 6.5% After First GAAP Profit And Higher Guidance - Has The Bull Case Changed?

Simply Wall St.04-05 19:26

In recent months, Mirum Pharmaceuticals reported very large year-over-year net product revenue growth, reached GAAP profitability, raised full-year revenue guidance to about US$500 million, and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625641024?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-05 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625641024","market":"nz","top_or_hot":-1,"title":"Mirum Pharmaceuticals (MIRM) Is Up 6.5% After First GAAP Profit And Higher Guidance - Has The Bull Case Changed?","media":"Simply Wall St.","content":"<div>\n<p>In recent months, Mirum Pharmaceuticals reported very large year-over-year net product revenue growth, reached GAAP profitability, raised full-year revenue guidance to about US$500 million, and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-65-after-first-gaap-profit\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mirum Pharmaceuticals (MIRM) Is Up 6.5% After First GAAP Profit And Higher Guidance - Has The Bull Case Changed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMirum Pharmaceuticals (MIRM) Is Up 6.5% After First GAAP Profit And Higher Guidance - Has The Bull Case Changed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-05 19:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-65-after-first-gaap-profit><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In recent months, Mirum Pharmaceuticals reported very large year-over-year net product revenue growth, reached GAAP profitability, raised full-year revenue guidance to about US$500 million, and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-65-after-first-gaap-profit\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRM","symbol_name":"Mirum Pharmaceuticals, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-65-after-first-gaap-profit","article_id":"2625641024","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/mirum-pharmaceuticals-mirm-is-up-65-after-first-gaap-profit","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625641024","pubTimestamp":1775388394,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In recent months, Mirum Pharmaceuticals reported very large year-over-year net product revenue growth, reached GAAP profitability, raised full-year revenue guidance to about US$500 million, and secured multiple new approvals and trial milestones for its rare disease portfolio, including LIVMARLI and CTEXLI.\nThis combination of improving financial performance and advancing late-stage studies, such as the EXPAND and VISTAS trials, is materially reshaping expectations for Mirum’s long-term rare...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIRM":"Mirum Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Mirum Pharmaceuticals(MIRM)在首次实现GAAP利润和更高指引后上涨6.5%-牛市情况发生变化了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":1.5},"content_text":"In recent months, Mirum Pharmaceuticals reported very large year-over-year net product revenue growth, reached GAAP profitability, raised full-year revenue guidance to about US$500 million, and secured multiple new approvals and trial milestones for its rare disease portfolio, including LIVMARLI and CTEXLI. This combination of improving financial performance and advancing late-stage studies, such as the EXPAND and VISTAS trials, is materially reshaping expectations for Mirum’s long-term rare disease franchise. We’ll now examine how Mirum’s first GAAP profitability and higher revenue guidance affect the company’s investment narrative and risk profile. AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementMirum Pharmaceuticals Investment Narrative RecapTo own Mirum, you need to believe its rare disease portfolio can support durable, profitable revenue, with LIVMARLI expanding beyond its initial liver indications and newer assets contributing over time. The most important near term catalyst remains clinical and regulatory progress that broadens LIVMARLI’s use, while a key risk is the company’s heavy reliance on this single franchise. The latest revenue guidance increase and GAAP profitability meaningfully strengthen the story, but do not change that core concentration risk. Among the recent developments, completion of enrollment in the EXPAND Phase 3 trial is especially relevant. It sets up a late 2026 readout that could meaningfully influence LIVMARLI’s addressable population and Mirum’s growth path. Together with the VISTAS PSC trial progress and higher revenue guidance of roughly US$500 million, this adds clinical and commercial milestones that investors may watch closely as potential inflection points for the stock. However, against this progress, growing scrutiny on high priced rare disease drugs could still challenge reimbursement and pricing power that investors should be aware of... Read the full narrative on Mirum Pharmaceuticals (it's free!)Mirum Pharmaceuticals’ narrative projects $794.3 million revenue and $102.1 million earnings by 2028. This requires 22.8% yearly revenue growth and a $160.7 million earnings increase from -$58.6 million today.Uncover how Mirum Pharmaceuticals' forecasts yield a $106.60 fair value, a 13% upside to its current price.Exploring Other PerspectivesMIRM 1-Year Stock Price Chart Some of the lowest ranked analysts were already assuming Mirum’s revenue would reach about US$713 million by 2028 with modest profitability, yet they still saw expectations as stretched compared with the risks around tougher reimbursement and upcoming trial results, so it is very possible that this new progress could shift those views in different directions.Explore 3 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth just $95.00!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Mirum Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.Our free Mirum Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mirum Pharmaceuticals' overall financial health at a glance.Searching For A Fresh Perspective?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Rare earth metals are the new gold rush. Find out which 26 stocks are leading the charge.The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625641024","isCrawlerRequest":true}